menu search

Cogent biosciences presents preclinical data highlighting precision oncology pipeline at the 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics

– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantage...

October 14, 2023, 4:30 pm

Biomea fusion announces appointment of juan pablo frías, m.d. as chief medical officer

Industry veteran and prominent diabetes clinical development expert to oversee Biomea’s progressing clinical development of novel ...

August 31, 2023, 12:30 pm

Biomea fusion: potential cure for diabetes, initiating with a buy

Biomea Fusion is a clinical-stage biotech company developing covalent small molecule inhibitors, with i...

July 16, 2023, 1:39 am

Biomea fusion stock soars after release of clinical data on diabetes treatment

Shares of Biomea Fusion Inc. BMEA, -5.89% jumped 17% in premarket trading Monday after the clinical-stage biopharmaceutical company released new clini...

June 26, 2023, 8:17 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion presents positive clinical data from the initial cohorts of the ongoing phase ii study (covalent-111) of bmf-219 in patients with type 2 diabetes mellitus at the american diabetes associ

Eight weeks after completing treatment with BMF-219, patients with type 2 diabetes (T2D) showed an increase of C-peptide and an improvement of HOMA-B,...

June 24, 2023, 1:54 am

Biomea fusion to present late breaking data from ongoing phase ii trial, covalent-111, evaluating bmf-219 in patients with type 2 diabetes at ada 2023

New clinical data from covalent-111 will be unveiled during a late-breaking poster presentation at ADA�...

June 20, 2023, 8:30 pm

Biomea fusion to present late breaking data from ongoing phase ii trial, covalent-111, evaluating bmf-219 in patients with type 2 diabetes at ada 2023

REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company ...

June 20, 2023, 4:30 pm

Biomea: novel approach to diabetes and cancer

BMEA develops oral covalent small molecules for cancer and diabetes. Its lead asset is a menin inhibito...

May 28, 2023, 7:57 am

Biomea fusion announces fda clearance of investigational new drug (ind) application for covalent menin inhibitor bmf-219 in type 2 diabetes

covalent-111, a Phase I/II clinical trial in patients with type 2 diabetes, already underway in Canada,...

December 14, 2022, 9:30 pm

Nurix therapeutics presents positive clinical results from its novel btk degrader (nx-2127) at the 64th american society of hematology (ash) annual meeting

Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton...

December 12, 2022, 10:30 pm

Biomea fusion to present new preclinical data showing bmf-219's strong activity in relapsed/refractory chronic lymphocytic leukemia (cll) tumor models at asco 2022

REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to dis...

May 26, 2022, 6:30 pm


Search within

Pages Search Results: